Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 4/20 | 0.35 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.34 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.34 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10345005 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRGBA1LMNATDP1 | |
| SCHEMBL10325111 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRGBA1LMNATDP1 | |
| SCHEMBL3620661 | 0.79 | ALDH1A1 (0.34) | ALDH1A1TSHRGBA1LMNATDP1 | |
| SCHEMBL8013317 | 0.79 | ALDH1A1 (0.34) | ALDH1A1TSHRGBA1LMNATDP1 | |
| SCHEMBL17982748 | 0.79 | ALDH1A1 (0.34) | ALDH1A1TSHRGBA1LMNATDP1 | |
| SCHEMBL8509956 | 0.79 | ALDH1A1 (0.34) | ALDH1A1TSHRGBA1LMNATDP1 | |
| SCHEMBL20607659 | 0.78 | ALDH1A1 (0.33) | ALDH1A1TSHRGBA1LMNATDP1 | |
| SCHEMBL27818667 | 0.76 | LGALS1 (0.36) | ALDH1A1TSHRLMNATDP1GAA | |
| SCHEMBL17610102 | 0.76 | LGALS1 (0.36) | ALDH1A1TSHRLMNATDP1GAA | |
| SCHEMBL6837637 | 0.76 | LGALS1 (0.36) | ALDH1A1TSHRLMNATDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130134-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4121060-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | Board of Regents, The University of Texas System (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115515601-A | Methods of treating viral infections with hexose-type monosaccharides and analogs thereof | 得克萨斯大学体系董事会 | 2022-12-23 | — | — | CN | disclosed |
| WO-2021188586-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-2663314-A2 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | The University of Texas M.D. Anderson Cancer (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20120276108-A1 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | INTERTECH BIO (US) | 2012-11-01 | — | — | US | disclosed |
| WO-2012097052-A2 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | INTERTECH BIO, LLC (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130134-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | G6PD, FBP1, ALDOA | ALDH1A1 525/4885TSHR 3732/4885GBA1 56/4885 |
| US-20120276108-A1 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | IGF1R, IRS1, IGFBP1 | ALDH1A1 1738/4885TSHR 1896/4885GBA1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.